Nevertheless, we pursued CLL-1 as a CAR T cell target for JMML as it provides the possibility of improved safety over other targeted therapies (like CD33 and CD123) because of its reduced expression on normal HSCs48 (Supplementary Fig. 5). This evidence concerns the gene CD33 and juvenile myelomonocytic leukemia.